Most Read Articles
20 Jun 2020
The Lundbeck Neuroscience Symposium was held at Sofitel KL Damansara over 2 days, with extensivediscussions on the management of various mental illnesses. The second day of the symposiumaddressed the topic of schizophrenia management, focusing on treatment goals, the rationale forpartial dopamine D(2) receptor agonism and the use of long-acting injectable (LAI) antipsychotics topromote adherence.
Pearl Toh, 5 days ago
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
4 days ago
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Christina Lau, 3 days ago

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.

Hydroxychloroquine a useful treatment for morphoea

27 May 2019

Treatment of morphoea with hydroxychloroquine results in a high response rate among patients, with a low rate of adverse effects, according to a recent study. However, prospective studies are warranted to establish its true efficacy.

A total of 84 patients (median age at diagnosis, 29.5 years) were included. Of these, 65 (77.4 percent) were female, 36 (42.9 percent) had a complete response to hydroxychloroquine, 32 (38.1 percent) had a partial response >50 percent, 10 (11.9 percent) had a partial response 50 percent, and six (7.1 percent) had no response. The median times to initial and maximal responses were 4 and 12 months, respectively.

In addition, there were 10 patients (11.9 percent) who had adverse effects from the study drug, the most common of which was nausea (n=6).

A retrospective study was conducted to assess the efficacy of hydroxychloroquine treatment of morphoea. The authors analysed patients who had morphoea and were treated with hydroxychloroquine monotherapy for at least 6 months from 1996 through 2013. They also examined the median times to initial and maximal responses.

This study, however, was limited by its retrospective design, according to the authors.

A rare fibrosing disorder of the skin and underlying tissues, morphoea is characterized by skin thickening and hardening due to excessive collagen deposition. According to Pope and Laxer, the “significance of the disease depends on the extent of the lesions, potential for functional disability or cosmetic disfigurement, and presence or absence of extracutaneous manifestations.” [Pediatr Clin North Am 2014;61:309-319]

Editor's Recommendations
Most Read Articles
20 Jun 2020
The Lundbeck Neuroscience Symposium was held at Sofitel KL Damansara over 2 days, with extensivediscussions on the management of various mental illnesses. The second day of the symposiumaddressed the topic of schizophrenia management, focusing on treatment goals, the rationale forpartial dopamine D(2) receptor agonism and the use of long-acting injectable (LAI) antipsychotics topromote adherence.
Pearl Toh, 5 days ago
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
4 days ago
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Christina Lau, 3 days ago

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.